Expectations trend
FY2028 · fiscal year ending 2028-04-30 · fmp
ALZAMEND NEURO INC (ALZN)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$1.55+1.31%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for ALZN yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
manage equity dilution and maintain listing status | A supporting condition in ALZAMEND NEURO INC's published investment case. The stated target is no further large equity sales and maintain Nasdaq listing. | Improving | additional large equity issuances or delisting occurs | Listing compliance regained vs target maintained Regained Nasdaq compliance (Sept 2026) after July notice; Series D preferred sale in Aug 2026. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2028 · fiscal year ending 2028-04-30 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Dec 8, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earningsObserved price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative clinical-development company, not a proven earnings compounder. The long-term thesis is in a watch state: AL001 has an early signal in trial data, but the evidence snapshot gives low confidence and the business is loss-making.
The valuation evidence is thin, so whether ALZN is cheap or expensive versus peers cannot be assessed. The snapshot does not show what the market already assumes; it does show that weak results, repeated earnings misses, and elevated risk remain central to expectations.
Near term, financial performance looks weak, and the risk of another earnings miss is elevated. Over the multi-year view, progress depends on clinical development of AL001, which showed a trend toward higher brain lithium exposure than inorganic lithium, while capital raising and unresolved Nasdaq compliance add uncertainty.
The long-term thesis hinges on whether AL001 advances beyond its early clinical signal and whether the company can manage funding and listing-compliance needs. Near term, weaker jobs data could add pressure to cyclical and healthcare names, while continued strength or weakness from healthcare bellwethers could support or weaken the sector backdrop.
For the next 1 to 3 years, ALZN remains a high-risk, low-confidence clinical-development story, with early promise outweighed by weak financial results and unresolved legal, regulatory, and funding risks. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| The company is advancing clinical trials and aims to meet big unmet medical needs. |
| Intact |
| failure to achieve key clinical milestones or trial setbacks |
Qualitative condition This condition has no defined numerical measure. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
improvement in EPS estimates | Recent analyst EPS estimates have improved from -0.98 to -0.67 next quarter. | Intact | mean EPS fails to improve or worsens beyond -0.7 next quarter | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
Unavailable → $-0.87 · observed estimates
Unavailable → $0.13B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | Unavailable | Unavailable | — / 0 |
| 2026-07-25 | Unavailable | Unavailable | — / 0 |
| 2026-07-26 | Unavailable | Unavailable | — / 0 |
| 2026-07-27 | Unavailable | Unavailable | — / 0 |
| 2026-07-28 | $-3.04 | $132,705,000 | 1 / 1 |
| 2026-07-29 | Unavailable | Unavailable | — / 0 |
| 2026-07-30 | Unavailable | Unavailable | — / 0 |
| 2026-07-31 | Unavailable | Unavailable | — / 0 |
| 2026-08-01 | Unavailable | Unavailable | — / 0 |
| 2026-08-02 | Unavailable | Unavailable | — / 0 |
| 2026-08-03 | Unavailable | Unavailable | — / 0 |
| 2026-08-04 | Unavailable | Unavailable | — / 0 |
| 2026-08-05 | Unavailable | Unavailable | — / 0 |
| 2026-08-06 | Unavailable | Unavailable | — / 0 |
| 2026-08-07 | $-3.04 | $132,705,000 | 1 / 1 |
| 2026-08-08 | Unavailable | Unavailable | — / 0 |
| 2026-08-09 | Unavailable | Unavailable | — / 0 |
| 2026-08-10 | Unavailable | Unavailable | — / 0 |
| 2026-08-11 | Unavailable | Unavailable | — / 0 |
| 2026-08-12 | Unavailable | Unavailable | — / 0 |
| 2026-08-13 | Unavailable | Unavailable | — / 0 |
| 2026-08-14 | $-3.04 | $132,705,000 | 1 / 1 |
| 2026-08-15 | $-3.04 | $132,705,000 | 1 / 1 |
| 2026-08-16 | $-3.04 | $132,705,000 | 1 / 1 |
| 2026-08-17 | $-3.04 | $132,705,000 | 1 / 1 |
| 2026-08-18 | $-3.04 | $132,705,000 | 1 / 1 |
| 2026-08-19 | $-3.04 | $132,705,000 | 1 / 1 |
| 2026-08-20 | $-3.04 | $132,705,000 | 1 / 1 |
| 2026-08-21 | $-0.87 | $132,705,000 | 1 / 1 |
| 2026-08-22 | $-0.87 | $132,705,000 | 1 / 1 |
| 2026-08-23 | $-0.87 | $132,705,000 | 1 / 1 |
| 2026-08-24 | $-0.87 | $132,705,000 | 1 / 1 |
| 2026-08-25 | $-0.87 | $132,705,000 | 1 / 1 |
| 2026-08-26 | $-0.87 | $132,705,000 | 1 / 1 |
| 2026-08-27 | $-0.87 | $132,705,000 | 1 / 1 |
| 2026-08-28 | $-0.87 | $132,705,000 | 1 / 1 |
| 2026-08-29 | $-0.87 | $132,705,000 | 1 / 1 |
| 2026-08-30 | $-0.87 | $132,705,000 | 1 / 1 |
| 2026-08-31 | $-0.87 | $132,705,000 | 1 / 1 |
| 2026-09-01 | $-0.87 | $132,705,000 | 1 / 1 |
| 2026-09-02 | $-0.87 | $132,705,000 | 1 / 1 |
| 2026-09-03 | $-0.87 | $132,705,000 | 1 / 1 |
| 2026-09-04 | $-0.87 | $132,705,000 | 1 / 1 |
| 2026-09-05 | $-0.87 | $132,705,000 | 1 / 1 |
| 2026-09-06 | $-0.87 | $132,705,000 | 1 / 1 |
| 2026-09-07 | $-0.87 | $132,705,000 | 1 / 1 |
| 2026-09-08 | $-0.87 | $132,705,000 | 1 / 1 |
| 2026-09-09 | $-0.87 | $132,705,000 | 1 / 1 |
| 2026-09-10 | $-0.87 | $132,705,000 | 1 / 1 |
| 2026-09-11 | $-0.87 | $132,705,000 | 1 / 1 |
| 2026-09-12 | $-0.87 | $132,705,000 | 1 / 1 |
| 2026-09-13 | $-0.87 | $132,705,000 | 1 / 1 |
| 2026-09-14 | $-0.87 | $132,705,000 | 1 / 1 |
| 2026-09-15 | $-0.87 | $132,705,000 | 1 / 1 |
| 2026-09-16 | $-0.87 | $132,705,000 | 1 / 1 |
| 2026-09-17 | $-0.87 | $132,705,000 | 1 / 1 |
| 2026-09-18 | $-0.87 | $132,705,000 | 1 / 1 |
| 2026-09-19 | $-0.87 | $132,705,000 | 1 / 1 |
| 2026-09-20 | $-0.87 | $132,705,000 | 1 / 1 |
| 2026-09-21 | $-0.87 | $132,705,000 | 1 / 1 |
| 2026-09-22 | $-0.87 | $132,705,000 | 1 / 1 |
| 2026-09-23 | $-0.87 | $132,705,000 | 1 / 1 |
| 2026-09-24 | $-0.87 | $132,705,000 | 1 / 1 |
| 2026-09-25 | $-0.87 | $132,705,000 | 1 / 1 |
| 2026-09-26 | $-0.87 | $132,705,000 | 1 / 1 |
| 2026-09-27 | $-0.87 | $132,705,000 | 1 / 1 |
| 2026-09-28 | $-0.87 | $132,705,000 | 1 / 1 |
| 2026-09-29 | $-0.87 | $132,705,000 | 1 / 1 |
| 2026-09-30 | $-0.87 | $132,705,000 | 1 / 1 |
| 2026-10-01 | $-0.87 | $132,705,000 | 1 / 1 |
| 2026-10-02 | $-0.87 | $132,705,000 | 1 / 1 |
| 2026-10-03 | $-0.87 | $132,705,000 | 1 / 1 |
| 2026-10-04 | $-0.87 | $132,705,000 | 1 / 1 |
| 2026-10-05 | $-0.87 | $132,705,000 | 1 / 1 |
| 2026-10-06 | $-0.87 | $132,705,000 | 1 / 1 |
| 2026-10-07 | $-0.87 | $132,705,000 | 1 / 1 |
| 2026-10-08 | $-0.87 | $132,705,000 | 1 / 1 |
| 2026-10-09 | $-0.87 | $132,705,000 | 1 / 1 |
| 2026-10-10 | $-0.87 | $132,705,000 | 1 / 1 |
| 2026-10-11 | $-0.87 | $132,705,000 | 1 / 1 |
| 2026-10-12 | $-0.87 | $132,705,000 | 1 / 1 |
| 2026-10-13 | $-0.87 | $132,705,000 | 1 / 1 |
| 2026-10-14 | $-0.87 | $132,705,000 | 1 / 1 |
| 2026-10-15 | $-0.87 | $132,705,000 | 1 / 1 |
| 2026-10-16 | $-0.87 | $132,705,000 | 1 / 1 |
| 2026-10-17 | $-0.87 | $132,705,000 | 1 / 1 |
| 2026-10-18 | $-0.87 | $132,705,000 | 1 / 1 |
| 2026-10-19 | $-0.87 | $132,705,000 | 1 / 1 |
| 2026-10-20 | $-0.87 | $132,705,000 | 1 / 1 |
| 2026-10-21 | $-0.87 | $132,705,000 | 1 / 1 |
| 2026-10-22 | $-0.87 | $132,705,000 | 1 / 1 |
| 2026-10-23 | $-0.87 | $132,705,000 | 1 / 1 |
| 2026-10-24 | $-0.87 | $132,705,000 | 1 / 1 |
| 2026-10-25 | $-0.87 | $132,705,000 | 1 / 1 |
| 2026-10-26 | $-0.87 | $132,705,000 | 1 / 1 |
| 2026-10-27 | $-0.87 | $132,705,000 | 1 / 1 |
| 2026-10-28 | $-0.87 | $132,705,000 | 1 / 1 |
| 2026-10-29 | $-0.87 | $132,705,000 | 1 / 1 |
| 2026-10-30 | $-0.87 | $132,705,000 | 1 / 1 |
| 2026-10-31 | $-0.87 | $132,705,000 | 1 / 1 |
| 2026-11-01 | $-0.87 | $132,705,000 | 1 / 1 |
| 2026-11-02 | $-0.87 | $132,705,000 | 1 / 1 |
| 2026-11-03 | $-0.87 | $132,705,000 | 1 / 1 |
| 2026-11-04 | $-0.87 | $132,705,000 | 1 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 1 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.